Join
Live feed
·
PRReleasevia Quantisnow
Adicet Bio Inc. logo

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

ByQuantisnow·Wall Street's wire, on your screen.
ACET· Adicet Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACET (Adicet Bio Inc.) and more on Quantisnow.